Previous 10 | Next 10 |
The US Food and Drug Administration (FDA) handed out its first-ever approval for the treatment of postpartum depression (PPD) on Tuesday (March 19) to biopharmaceutical giant Sage Therapeutics (NASDAQ: SAGE ). Called Zulresso (generic name brenaxolone), the drug will be available ...
Sage Therapeutics (NASDAQ: SAGE ) has priced its postpartum depression (PPD) med Zulresso (brexanolone) at $7,450 per vial or $34,000 per average course of treatment (before discounts). More news on: Sage Therapeutics, Inc., Marinus Pharmaceuticals, Inc., Healthcare stocks news, Sto...
Marinus Pharmaceuticals (NASDAQ: MRNS ): FY GAAP EPS of -$0.90. Cash and Cash equivalents of $67.72M. Press Release More news on: Marinus Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
RADNOR, Pa., March 11, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development ac...
RADNOR, Pa., March 06, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today a...
The9 (NASDAQ: NCTY ) +43% . More news on: The9 Limited, Cool Holdings Inc., Document Security Systems, Inc, Stocks on the move, Read more ...
RADNOR, Pa., March 05, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Edward Sm...
RADNOR, Penn., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today...
Breakout Stock Portfolio 2019 results YTD Cumulative Weekly Max Gain YTD: +61.60% Cumulative Gain by Friday of the Week: -3.60% This week 3 out of 4 breakout stocks for members reached double digits during a short trading week. Selling of the breakout stocks prior to the end of t...
RADNOR, Pa., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Christophe...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...